Skip to content
Subscribe Follow on LinkedIn

Latest

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

✨ Onyx Summary Kyverna Therapeutics reported updated Phase 1 data from investigator-initiated trials of its CD19 CAR T-cell therapy, KYV-101, in progressive multiple sclerosis, showing favorable safety, CNS penetration, and early signs of disease stabilization or improvement. The data, presented by Stanford and UCSF at the 2025 ECTRIMS Congress, reinforce KYV-101’

PowerTrack and Stem, Inc.’s Push for Renewable Confidence

PowerTrack and Stem, Inc.’s Push for Renewable Confidence

"The CEO’s role isn’t operational - it’s to set the long-term vision and take the risk buffer so others can take the micro bets that are needed to help grow the business,” Arun Narayanan explains why long-term thinking is essential to scaling sustainable energy.

Advanced Clinical Announces Leadership Transition

Advanced Clinical Announces Leadership Transition

✨ Onyx Summary Advanced Clinical announced that CEO Julie Ross has departed to pursue a new opportunity, with Founder and Owner Leo Sheridan assuming the role of Chief Executive Officer. Supported by a seasoned leadership team, the transition underscores the company’s continued focus on global growth, operational excellence, and delivering

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

✨ Onyx Summary Cellares appointed Chris McDonald, former SVP and Global Head of Technical Operations at Kite (a Gilead Company), to its Advisory Board. McDonald brings more than 35 years of experience scaling global biomanufacturing operations at Kite, Amgen, Novartis, and AstraZeneca, expertise that will support Cellares’ international expansion of its

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

✨ Onyx Summary Lexicon Pharmaceuticals announced that the FDA will require additional time to review newly submitted clinical data supporting the potential resubmission of its New Drug Application for Zynquista® (sotagliflozin) as an adjunct therapy for adults with type 1 diabetes, with feedback now expected in Q4 2025. The update follows

MassBio and Google empower biotech workers with AI for Drug Discovery Training

MassBio and Google empower biotech workers with AI for Drug Discovery Training

✨ Onyx Summary MassBio and Google co-hosted the 2025 AI for Drug Discovery Training in Cambridge, bringing together more than 60 life sciences professionals from start-ups, academia, and pharma for hands-on sessions with Google’s Gemini and Vertex AI platforms. By equipping the Massachusetts biotech community with AI-driven skills, the program

Launching the Palmetto Beacon Venture Fellowship: Building a stronger investor ecosystem

Launching the Palmetto Beacon Venture Fellowship: Building a stronger investor ecosystem

✨ Onyx Summary MassBio, SCbio, Venture Carolina, VentureSouth, and the South Carolina Department of Commerce launched the Palmetto Beacon Venture Fellowship, a program designed to educate and empower the next generation of biotech investors through immersive sessions in Charleston, John’s Island, and Boston. By bridging ecosystems from the Southeast to

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

✨ Onyx Summary Lexicon Pharmaceuticals presented new Phase 2b PROGRESS study data for its investigational AAK1 inhibitor, pilavapadin, at the NEUROdiab and EASD 2025 meetings, showing that the 10 mg once-daily dose achieved a statistically and clinically meaningful reduction in diabetic peripheral neuropathic pain while maintaining strong tolerability. The findings strengthen

Feeding the Future: Inside Aurélio Pavinato’s Big Dream for Agriculture

Feeding the Future: Inside Aurélio Pavinato’s Big Dream for Agriculture

"Our dream is to positively impact upon future generations, by being the leader in global efficiency in the agricultural sector, and, above all, to respect the planet,” Dr. Aurélio Pavinato outlines why soil health and circularity are central to SLC Agrícola's long-term growth.

Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q’s Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control

Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q’s Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control

✨ Onyx Summary Cellares announced multiple technology partnerships to advance Cell Q™, the first fully automated, modular quality control platform designed to handle the commercial-scale throughput required for cell therapy manufacturing. By integrating best-in-class systems from partners like Tecan, Cytek, and Advanced Instruments, Cell Q sets a new standard for compliance,